Alexander Tatangelo
Family · Pittsburgh, PANPI 1891270997
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 71.9% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $10,835, 9.3 times the $1,160 reported in 2021. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 428 payments — averaging $46.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$14K
- Viiv Healthcare Company$3K
- AbbVie$737
- Merck$480
- Alkermes, Inc.$275
- Antares Pharma, Inc.$246
- plus $708 from 14 others
What the payments were for
- Consulting fees$2,04010%
- Speaking & faculty fees$7,08335%
- Travel & lodging$2,64513%
- Food & beverage$8,28341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 145 | $14,407 |
| Viiv Healthcare Company | 151 | $3,197 |
| AbbVie | 45 | $737 |
| Merck | 25 | $480 |
| Alkermes, Inc. | 13 | $275 |
| Antares Pharma, Inc. | 12 | $246 |
| Organon | 7 | $141 |
| Novo Nordisk | 5 | $114 |
| Exact Sciences | 6 | $113 |
| Indivior Inc. | 5 | $93 |
| Halozyme Inc | 2 | $39 |
| Braeburn Inc. | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 1 | $30 |
| Lilly USA, LLC | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Dynavax Technologies Corporation | 2 | $21 |
| Verity Pharmaceuticals Inc. | 1 | $21 |
| Pfizer | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Theratechnologies Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,050 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DescovyEmtricitabine/Tenofov Alafenam | 102 | $216,087 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 26 | $97,800 |
| ApretudeCabotegravir | 15 | $58,911 |
| TivicayDolutegravir Sodium | 24 | $51,919 |
| CabenuvaCabotegravir/Rilpivirine | 13 | $50,423 |
| DovatoDolutegravir Sodium/Lamivudine | 20 | $45,635 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $43,089 |
| OzempicSemaglutide | 34 | $32,714 |
| MounjaroTirzepatide | 14 | $14,724 |
| XareltoRivaroxaban | 23 | $12,857 |
| JardianceEmpagliflozin | 18 | $8,486 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,536 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,186 |
| Estradiol (Twice Weekly)Estradiol | 36 | $3,980 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $2,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy, Biktarvy, Genvoya | $14,407 | $356,977139 claims |
| Viiv Healthcare CompanyApretude, Tivicay, Cabenuva, Dovato | $3,197 | $206,88872 claims |
| Novo NordiskOzempic | $114 | $32,71434 claims |
| Lilly USA, LLCMounjaro | $28 | $14,72414 claims |
| Johnson & JohnsonXarelto | $17 | $12,85723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Pittsburgh
- Kathleen ScholzPittsburgh$397K
- Kweilynn GreenePittsburgh$139K
- Margaret RosenzweigPittsburgh$89K
- Patricia HabdasPittsburgh$83K
- Morgan ColePittsburgh$41K
- Amber GrinnellPittsburgh$33K
- Matthew BarnesPittsburgh$25K
- Sydney MurrayPittsburgh$19K
- Renee ConnPittsburgh$15K
- Shannon FitzgeraldAllison Park$370K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.